Entera Bio(ENTX) - 2019 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenues for the nine months ended September 30, 2019, were $134,000 from services provided to Amgen under their licensing agreement [55] - Total operating expenses for the same period were $7.9 million, with research and development expenses at $5.2 million and general and administrative expenses at $2.8 million [56] - Total cash as of September 30, 2019, was $5.9 million, expected to fund operations into the first quarter of 2020 [56] Business Line Data and Key Metrics Changes - The company is focusing on its lead program, EB613, for osteoporosis, which is seen as a highly de-risked Phase 2 candidate with a well-defined Phase 3 clinical trial design [12][15] - The secondary program, EB612, for hypoparathyroidism, reported positive results from a Phase 2 study, confirming effective delivery into the bloodstream [29] Market Data and Key Metrics Changes - The osteoporosis market is expected to grow significantly, particularly in regions like China due to aging populations and increased affordability of drugs [18][50] - The company is exploring opportunities in both China and Japan, with strong interest in collaboration regarding its lead programs [51] Company Strategy and Development Direction - The company aims to transform the treatment paradigm for osteoporosis by introducing a less expensive, once-daily oral tablet, targeting the 90% of osteoporotic patients who are not currently treated [16][17] - There is a commitment to executing lead programs, developing new candidates in large markets, and engaging in targeted business development efforts [15][20] Management's Comments on Operating Environment and Future Outlook - Management believes 2020 will be a critical year with significant data readouts expected from the Phase 2 osteoporosis program [58] - The recent recall of a competitor's product has heightened awareness for better therapies in the market, which may benefit the company's programs [68] Other Important Information - The company has established its U.S. headquarters in Boston and is expanding its team to support business development and regulatory efforts [20] - The collaboration with Amgen for an anti-inflammatory agent has progressed well, with positive results from studies conducted [33] Q&A Session Summary Question: Impact of Takeda's Natpara recall on EB612 program - Management noted that the recall has created heightened awareness regarding the need for better therapies, which could benefit both their programs [68] Question: Size of Phase 3 trial for EB612 - The anticipated Phase 3 program for EB612 is expected to include around 100 to 150 patients, typical for orphan indications [72]